

1 **Variation in Aerosol Production Across Oxygen Delivery Devices in**
2 **Spontaneously Breathing Human Subjects**

3
4 Theodore J. Iwashyna, MD, PhD /1,2/

5 Andre Boehman, PhD /3/

6 Jesse Capecehatro, PhD /3/

7 Amy M. Cohn, PhD /4/

8 James M. Cooke, MD /5,6/

9 Deena Kelly Costa, PhD, RN /7/

10 Richard M. Eakin, RT, *RRT-ACCS* /8/

11 Hallie C. Prescott /1,2/

12 Margaret S. Woolridge, PhD /3,9/

13
14 1/ VA Center for Clinical Management Research

Ann Arbor Veteran Affairs Health System, Ann Arbor, Michigan, USA

16
17 2/ Medicine

18 3/ Mechanical Engineering

19 4/ Industrial & Operations Engineering

20 5/ Family Medicine

21 6/ Learning Health Sciences

22 7/ Nursing

23 8/ Respiratory Care

24 9/ Aerospace Engineering

25
26 at the University of Michigan, Ann Arbor, Michigan, USA

27
28 Acknowledgements: We would like to thank Gene Kim and Lee Kamphuis for their
29 administrative support.

30
31 Funding: None. This material is the result of work supported with resources and use of
32 facilities at the Ann Arbor VA Medical Center.

33
34 Disclaimer: This work does not necessarily represent the views of the US Government
35 or Department of Veterans Affairs.

36
37 Word Count 1261

38
39 Corresponding Author

40 Theodore J Iwashyna, MD, PhD

41 2800 Plymouth Road

42 NCRC Building 16, Room 326W

43 Ann Arbor, MI. 48109

44 Email: tiwashyn@umich.edu

45 Twitter: [@iwashyna](https://twitter.com/iwashyna)

46 Heated high-flow nasal cannula (HHFNC) has emerged as an important life support tool
47 for patients with acute hypoxemic respiratory failure, especially for patients in whom
48 intubation may be riskier or incompatible with their goals of care. It may also have an
49 important role in facilitating extubation.^{1,2}

50
51 Despite the central importance of hypoxemic respiratory failure as a mechanism of
52 mortality in COVID19, several authorities have recommended against the use of heated
53 high-flow nasal cannula in patients with suspected or confirmed COVID19.³⁻⁵ These
54 recommendations are driven in part by data of dispersion and stability of SARS-CoV-2
55 in clinical spaces⁶⁻⁸, and fears that high flow rates will increase aerosolization of SARS-
56 CoV-2, including by data from an artificial simulator using a smoke dispersion model.^{9,10}
57 In contrast, lower flow oxygen is routinely assumed to present an acceptable risk of
58 aerosol dispersion. Therefore, in order to inform care policy for COVID19 patients at the
59 VA Ann Arbor and University of Michigan regarding infection control under oxygen
60 support, we sought to assess whether HHFNC results in greater production of
61 aerosolized particles than 6 liters per minute nasal cannula, using state-of-the-art
62 techniques of aerosol measurement, in spontaneously breathing human volunteers in a
63 simulated hospital room.

64 65 **Methods**

66
67 This work was conducted as a quality improvement project in order to inform care policy
68 for COVID19 patients at the VA Ann Arbor and University of Michigan regarding
69 infection control under oxygen support, and reviewed and deemed not regulated by the
70 University of Michigan Institutional Review Board (HUM00179622).

71
72 For each volunteer, we first measured background aerosol levels in the room
73 immediately prior to testing. We then measured aerosol levels while the healthy
74 volunteer laid in bed—with the head of bed at 30 degrees—wearing the following
75 oxygen delivery devices: (a) 6L/min nasal canula (NC) with humidification; (b) non-re-
76 breather mask (NRB) with 15L/min gas flow, non-humidified; (c) HHFNC with 30L/min
77 gas flow; (d) HHFNC with 60L/min gas flow. Two scanning mobility particle sizing
78 (SMPS) systems (TSI 3080/3030, TSI 3080/3750) were used to measure aerosols 10 to
79 500 nanometer (nm) in size for each of the oxygen delivery devices. Additional
80 measurements were made during HHFNC use for larger particles (from 10 to 10,000 nm
81 in size) using two particles counters (PCs; TSI 3030, TSI 3330). For reference, testing
82 was performed with a low aerosolization control (HEPA filter) and 2 high aerosolization
83 controls (with a candle burning, and with a water nebulizer).

84
85 The SMPS aerosol measurement probes were placed in two locations (**Figure 1**)
86 selected for their clinical relevance: (#1) affixed to the bed rail beside the patient's head
87 (mimicking where someone would stand to perform suctioning or oral care). The probe
88 at location #1 was also relocated to a second position (#2) to approximately 10 cm from
89 the patient's mouth for each oxygen delivery device test. The particle counters
90 measurements were made at position (#2).

91

92 Aerosol measurements were obtained using the SMPS and PC systems, which reliably
93 assess the distribution of particles of size 10 to 10,000 nm, the relevant range for
94 human coughing.¹¹

95
96 Each sample was collected for three minutes and data were acquired for approximately
97 a 10-minute period for each oxygen delivery device. The healthy volunteers were
98 instructed to intentionally cough at each setting; spontaneous coughing occurred for
99 some volunteers throughout and was not suppressed in any way. The simulated
100 hospital room matched the dimensions, shape and layout of a single occupancy hospital
101 room with all equipment, monitors and computers standard to this setting. Standard wall
102 gas supplies and regulators were used with compressed air substituted for
103 supplemental oxygen. Investigators wore standard surgical face masks and remained in
104 the room and stationary for each extended sampling period to minimize air disturbance.
105 We recorded each sampling period (video and audio) for reference and data archiving.

106 107 **Data Analysis**

108
109 For each aerosol sample, the particle size distribution, the total number of particles, the
110 total mass of particles and the average particle size were measured

111 112 **Results**

113
114 Four healthy volunteers from the authorship group participated, 2 male (Patients 1 and
115 2) and 2 female (Patients 3 and 4). None had known lung disease, recent exposure to
116 COVID-19 or other sick contacts, or recent travel to a known area of transmission. No
117 testing occurred with the volunteers wearing masks.

118
119 **Figure 2** shows particle mass concentrations among the first 3 patients; note the log
120 vertical scale. As seen in the figure, there was variation in baseline measurements (i.e.,
121 room air) day-to-day. Samples of the room air are included for reference in **Figure 2** at
122 measurement location #1, the head of the bed. (Patients 1 and 2 were done on one day,
123 Patient 3 on another.) As seen in the bottom center of the figure, HEPA filtration caused
124 an order of magnitude decrease in particle concentrations, and the burning of a candle
125 caused an order of magnitude increase in particle concentrations. Similar increases
126 were seen with the nebulizer (data not shown). There was no variation in aerosol level
127 within patients between room air, 6 L/min NC, 15 L/min NRB, 30 L/min HHFNC, and 60
128 L/min HHFNC, regardless of coughing. Consistent results are shown in **Figure 3** for the
129 particle number concentration (via SMPS), and in **Figure 4** for average particle diameter
130 (via SMPS).

131
132 Measurements with the Patients 1, 3, and 4, that included broader range of particles, up
133 to 10,000 nm (=10 micron), also showed consistently no increase above the room levels
134 of particle number concentration during HHFNC use at 30 L/min or 60 L/min (**Appendix**
135 **1**). (These tests were repeated for Patients 1, 3, and 4 on a third testing day with the
136 particle counters at position #2 in **Figure 1**.)

137

138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166

Conclusion

In these healthy human volunteers, there was no evidence of increased aerosolization with nasal cannula, non-rebreather mask, or heated high flow nasal cannula in the particle size range of 10 nm to 10000 nm. This may contrast with the interpretation of another study that used mannequins and an intentional addition of smoke to their model of the right middle lobe of the lung as a measure, although the actual dispersion distances shown in that study are similar.⁹ In contrast, Loh *et al* reported visible assessments of gargled food dye in each of 5 patients who coughed twice, which showed highly variable changes in coughing distance from a reduction of 2 cm to an increase fo 84 cm using HHFNC compared to spontaneous breathing.¹² Our data are consistent with Leung *et al*'s culture-based data showing no increased dispersion in infectious organisms with the use of HHFNC in ICU patients with pneumonia.¹³

A limitation of the present study is the modest numbers of volunteers, with consequent limitations in the degree of variation in naso/oral structures. None of these human subjects had an active viral syndrome—although also neither did any of the test mannequins in prior data. These data do not speak to the aerosolization potential of other modalities, nor to debates about the relative merits of early intubation and volume limitation versus spontaneous breathing with heated high flow nasal cannula in the acute respiratory distress syndrome. Debate about the correct biophysical conceptualization of droplet spread remains.¹⁴ Despite these limitations, these data doprovide direct evidence that there may be limited differences in aerosolization between alternative modes of oxygen delivery at clinically relevant distances and positions for routine care.

Preprint

167 **References**

- 168
- 169 1. Hernandez G, Vaquero C, Colinas L, et al. Effect of Postextubation High-Flow
170 Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation
171 Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. *JAMA*.
172 2016;316(15):1565-1574.
 - 173 2. Hernandez G, Vaquero C, Gonzalez P, et al. Effect of Postextubation High-Flow
174 Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk
175 Patients: A Randomized Clinical Trial. *JAMA*. 2016;315(13):1354-1361.
 - 176 3. Wax RS, Christian MD. Practical recommendations for critical care and
177 anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. *Can J*
178 *Anaesth*. 2020.
 - 179 4. Department of Veterans Affairs (VA) Veterans Health Administration (VHA).
180 *STANDARD OPERATING PROCEDURE (SOP): Interim Guidance for Medical*
181 *Management of Hospitalized COVID-19 Patients, March 21, 2020*. 2020.
 - 182 5. Respiratory Therapy Group of the Chinese Medical Association Respiratory
183 Branch. Expert Consensus on Respiratory Therapy Related to New Coronavirus
184 Infection in Severe and Critical Patients. *Chinese Journal of Tuberculosis and*
185 *Respiratory Medicine*. 2020;17:eRelease ahead of print.
 - 186 6. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe
187 Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China,
188 2020. *Emerg Infect Dis*. 2020;26(7).
 - 189 7. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability
190 of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. 2020.
 - 191 8. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on
192 inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect*.
193 2020;104(3):246-251.
 - 194 9. Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal
195 cannula therapy versus CPAP via different masks. *The European respiratory*
196 *journal*. 2019;53(4).
 - 197 10. Namendys-Silva SA. Respiratory support for patients with COVID-19 infection.
198 *The Lancet Respiratory medicine*. 2020.
 - 199 11. Zayas G, Chiang MC, Wong E, et al. Cough aerosol in healthy participants:
200 fundamental knowledge to optimize droplet-spread infectious respiratory disease
201 management. *BMC Pulm Med*. 2012;12:11.
 - 202 12. Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC)
203 on coughing distance: implications on its use during the novel coronavirus
204 disease outbreak. *Can J Anaesth*. 2020.
 - 205 13. Leung CCH, Joynt GM, Gomersall CD, et al. Comparison of high-flow nasal
206 cannula versus oxygen face mask for environmental bacterial contamination in
207 critically ill pneumonia patients: a randomized controlled crossover trial. *J Hosp*
208 *Infect*. 2019;101(1):84-87.
 - 209 14. Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions:
210 Potential Implications for Reducing Transmission of COVID-19. *JAMA*. 2020.
- 211
- 212


213
214
215
216
217
218

Figure 1: Examples of measurement location and test set-up. All photographed individuals are named authors on the manuscript and this is used with their permission.



219
220
221
222

223 **Figure 2: Particle mass concentration (SMPS)**
224




225
226

227 **Figure 3: Particle number concentration (SMPS)**

228

229




230

231

232
233
234
235
236

Figure 4: Average particle diameter (SMPS).




237
238

239
240
241
242
243
244


Appendix – Data from Broader range Particle Counters for Patients 1, 3, and 4.

Figure A1: Particle size distributions (SMPS) of room air and 60 L/min HHFNC




245
246
247

Figure A2: Particle number concentration (PC) room air and 60 L/min HHFNC




248

249 **Figure A3:** Particle mass concentration (PC) 60 L/min HHFNC and room air.



250
251
252

Figure A4: Particle number concentration (PC) 60 L/min HHFNC and room air.




253
254
255
256

(a)

(b)

Figure A5: Total number of particles (PC) 60 L/min HHFNC and room air



257